Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
Type:
Grant
Filed:
March 23, 2020
Date of Patent:
November 24, 2020
Assignee:
CALITHERA BIOSCIENCES, INC.
Inventors:
Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
Abstract: A process for solubilization and refolding of precursor insulin or insulin analogs from inclusion body isolates for use in the production of insulin or insulin analog is described.
Type:
Grant
Filed:
August 29, 2016
Date of Patent:
August 18, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Allison D. Ortigosa, Rebecca A. Chmielowski, Mark C. Sleevi
Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
August 11, 2020
Assignee:
The Broad Institute, Inc.
Inventors:
Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
Type:
Grant
Filed:
June 16, 2016
Date of Patent:
July 14, 2020
Assignee:
GW Research Limited
Inventors:
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Abstract: The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.
Abstract: Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.
Type:
Grant
Filed:
July 19, 2013
Date of Patent:
June 9, 2020
Assignee:
Impact Therapeutics, Inc.
Inventors:
Suixiong Cai, Ye Edward Tian, Sishun Kang, Zheng Meng, Chengyun Gu, Feng Yin, Shengzhi Chen, Yang Zhang, Xiuyan Zhang, Hongqiang Fei, Dongmei Wang
Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
March 3, 2020
Assignee:
Array BioPharma Inc.
Inventors:
Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
February 25, 2020
Assignee:
Array BioPharma Inc.
Inventors:
Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
Abstract: The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
January 7, 2020
Assignee:
DIMERIX BIOSCIENCE PTY LTD.
Inventors:
Kevin D. G. Pfleger, Elizabeth McCall, James Williams
Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and at least one phenylpyrazole and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and at least one phenylpyrazole.
Abstract: The present invention is related to a compound of formula (I): a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N—R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.
Type:
Grant
Filed:
June 11, 2018
Date of Patent:
September 24, 2019
Assignee:
Centogene AG
Inventors:
Matthias Beller, Jan Lukas, Moritz Frech, Christian Junghanss, Anahit Pews-Davtyan
Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
Type:
Grant
Filed:
March 13, 2017
Date of Patent:
September 3, 2019
Assignee:
Heron Therapeutics, Inc.
Inventors:
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
Inventors:
Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
Abstract: A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of ?4?1, ?5?1, ?4?7, ?v?3 and ?L?2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
May 14, 2019
Assignee:
TEXAS HEART INSTITUTE
Inventors:
Ronald J. Biediger, William C. Gundlach, IV, Robert V. Market, Michael M. Savage, Peter Vanderslice
Abstract: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.
Type:
Grant
Filed:
June 2, 2014
Date of Patent:
April 30, 2019
Assignee:
Emory University
Inventors:
Stephen F. Traynelis, Dennis C. Liotta, Rose M. Santangelo, Ethel C. Garnier
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
Type:
Grant
Filed:
July 1, 2014
Date of Patent:
April 9, 2019
Assignees:
Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
Inventors:
Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani